2023年,全球ADC领域发生了20多起并购和合作授权交易,ADC和偶联药的市场达到了空前的热潮。中国本土药企在ADC重磅交易的大潮中表现亮眼,展示了本土药企在新药研发领域的技术创新实力。据沙利文披露的数据显示,截至2023年12月,全球已有超过200款ADC分子处于临床开发阶段。临床新靶点的数量也创历史新高,HER2、TROP2传统靶点热度不减,而新靶点HER3、Claudin18.2、EGFR也在临床中展现出了显著的疗效。
2024年ADC领域的火爆仍在继续,多个ADC Biotech被MNC并购,行业热度只增不减,2024被视为是持续高速发展的时期。第三届生物偶联药全球创新峰会(Global XDC2024)将于今年9月再次在中国无锡举行,由药明合联和佰傲谷BioValley共同主办。大会以“探索偶联药的无限可能”为主题,将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术,以及CMC挑战和商业化策略等内容,引领ADC开发新范式。
本届峰会邀请了众多生物偶联药领域的国际专家与会,共同探讨创新合作,碰撞思想,助力生物偶联药行业蓬勃发展。
Keynote Speech
Rina-S-the missing link(er)
Protein homeostasis by dual-precision targeted protein degradation and stabilization
A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
NTX1105: development of a best-in-class ADC targeting Nectin-4
Collaborating within the global life science ecosystem to advance breakthrough science
论坛一:Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies
Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system
Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
CS5001, a potential best-in-class ROR1 ADC
Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
Polysorbates in biopharmaceuticals-approaches to mitigate risk
论坛二:Bioconjugates development beyond ADCs
RDC-the exploration of new drug modality in unmet clinical need
Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
Fully human common light chain technology for novel ADCs
论坛三:Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)
Harnessing AbClick Pro®for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
An overview on the new topoisomerases inhibitors technologies
Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)
论坛四:CMC challenges and commercialization strategies
CMC scale-up challenges and COGs for site specific ADCs
Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
The integrated analytical platform enables accelerated CMC development of XDCs
QbD considerations for ADC process
How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
Non-clinical strategies for ADC drugs
更多确认嘉宾及议题持续公布中.....
主办单位
药明合联WuXi XDC、佰傲谷BioValley
时间地点
2024年9月10-12日(周二/周三/周四)
中国·无锡君来洲际酒店
报名方式
欢迎更多XDC研发企业加入!
标准通票:200元/人
温馨提示:如您收到主办方特别邀请,请通过特别邀请链接或者二维码进行注册登记,无需购买标准通票。
转发赢门票:转发本篇推文至朋友圈,集赞28个,即可获取标准通票一张(不含餐)。
联系我们
定制参展/商务合作请联系:Stephen Sun 15966587556(微信同号)
参会报名/媒体合作请联系:Abby Jiang18217659261(微信同号)
特别感谢
头枕太湖,北依长江
9月无锡,温和飒爽
Global XDC 2024
期待您的莅临~
2023年,全球ADC领域发生了20多起并购和合作授权交易,ADC和偶联药的市场达到了空前的热潮。中国本土药企在ADC重磅交易的大潮中表现亮眼,展示了本土药企在新药研发领域的技术创新实力。据沙利文披露的数据显示,截至2023年12月,全球已有超过200款ADC分子处于临床开发阶段。临床新靶点的数量也创历史新高,HER2、TROP2传统靶点热度不减,而新靶点HER3、Claudin18.2、EGFR也在临床中展现出了显著的疗效。
2024年ADC领域的火爆仍在继续,多个ADC Biotech被MNC并购,行业热度只增不减,2024被视为是持续高速发展的时期。第三届生物偶联药全球创新峰会(Global XDC2024)将于今年9月再次在中国无锡举行,由药明合联和佰傲谷BioValley共同主办。大会以“探索偶联药的无限可能”为主题,将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术,以及CMC挑战和商业化策略等内容,引领ADC开发新范式。
本届峰会邀请了众多生物偶联药领域的国际专家与会,共同探讨创新合作,碰撞思想,助力生物偶联药行业蓬勃发展。
Keynote Speech
Rina-S-the missing link(er)
Protein homeostasis by dual-precision targeted protein degradation and stabilization
A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
NTX1105: development of a best-in-class ADC targeting Nectin-4
Collaborating within the global life science ecosystem to advance breakthrough science
论坛一:Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies
Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system
Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
CS5001, a potential best-in-class ROR1 ADC
Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
Polysorbates in biopharmaceuticals-approaches to mitigate risk
论坛二:Bioconjugates development beyond ADCs
RDC-the exploration of new drug modality in unmet clinical need
Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
Fully human common light chain technology for novel ADCs
论坛三:Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)
Harnessing AbClick Pro®for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
An overview on the new topoisomerases inhibitors technologies
Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)
论坛四:CMC challenges and commercialization strategies
CMC scale-up challenges and COGs for site specific ADCs
Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
The integrated analytical platform enables accelerated CMC development of XDCs
QbD considerations for ADC process
How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
Non-clinical strategies for ADC drugs
更多确认嘉宾及议题持续公布中.....
主办单位
药明合联WuXi XDC、佰傲谷BioValley
时间地点
2024年9月10-12日(周二/周三/周四)
中国·无锡君来洲际酒店
报名方式
欢迎更多XDC研发企业加入!
标准通票:200元/人
温馨提示:如您收到主办方特别邀请,请通过特别邀请链接或者二维码进行注册登记,无需购买标准通票。
转发赢门票:转发本篇推文至朋友圈,集赞28个,即可获取标准通票一张(不含餐)。
联系我们
定制参展/商务合作请联系:Stephen Sun 15966587556(微信同号)
参会报名/媒体合作请联系:Abby Jiang18217659261(微信同号)
特别感谢
头枕太湖,北依长江
9月无锡,温和飒爽
Global XDC 2024
期待您的莅临~